microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

  • S. Rossi
  • M. Shimizu
  • E. Barbarotto
  • M. S. Nicoloso
  • F. Dimitri
  • D. Sampath
  • M. Fabbri
  • S. Lerner
  • L. L. Barron
  • L. Z. Rassenti
  • L. Jiang
  • L. Xiao
  • J. Hu
  • P. Secchiero
  • G. Zauli
  • S. Volinia
  • M. Negrini
  • W. Wierda
  • T. J. Kipps
  • W. Plunkett
  • K. R. Coombes
  • L. V. Abruzzo
  • M. J. Keating
  • G. A. Calin
ORKG logo View in ORKG
Publication date
January 2010
Publisher
American Society of Hematology
ISSN
0006-4971
Citation count (estimate)
164

Abstract

Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitative reverse-transcription polymerase chain reaction (qRT-PCR) profiling in 104 CLL patients with a well-defined chromosome 17p status, and we validated our findings with miRNA microarray data from an independent cohort of 80 patients. We found that miR-15a, miR-21, miR-34a, miR-155, and miR-181b were differentially expressed between CLLs with chromosome 17p deletion and CLLs with normal 17p and normal karyotype, and that miR-181b was down-regulated in therapy-refractory cases. miR-21 expression le...

Extracted data

We use cookies to provide a better user experience.